The highly publicized decision by President Obama to add more federal dollars toward embryonic stem cell research may be fueling misconceptions about how drugs and medical products are created. But it's a part of the debate on stem cells that some in medicine think needs to be heard. Dr. Scott Gottlieb, former Food and Drug Administration deputy commissioner and resident fellow at the American Enterprise Institute, discusses with host Bruce Japsen funding realities, and what he sees as misconceptions related to the National Institutes of Health's new funding powers in the area of embryonic stem cells.
